McMaster University

TATAA Announces Formation of Scientific Advisory Board

Retrieved on: 
Tuesday, October 31, 2023
Drug development, OpenBiome, PPD, MIT, AstraZeneca, MPH, McMaster University, MD, Medicinal chemistry, Doctor of Philosophy, Research, ChromeOS, Internal medicine, Growth, Pharmacy, Novartis, Innate immune system, Medicine, Bristol Myers Squibb, Amgen, Drug discovery, Molecular biology, Biomarker, Nobel Prize, United States Air Force Scientific Advisory Board, SAB, Harvard University, Medical device, Pharmaceutical industry, Physiology, Fluid dynamics, Gastroenterology, Ultragenyx, TATAA, Western University, Bioanalysis

GOTHENBURG, Sweden, Oct. 31, 2023 /PRNewswire/ -- TATAA Biocenter (the "Company" or "TATAA"), a leading global CRO for high-quality molecular analysis, announced the formation of its Scientific Advisory Board ("SAB").

Key Points: 
  • GOTHENBURG, Sweden, Oct. 31, 2023 /PRNewswire/ -- TATAA Biocenter (the "Company" or "TATAA"), a leading global CRO for high-quality molecular analysis, announced the formation of its Scientific Advisory Board ("SAB").
  • "We are excited to have such a distinguished group of experts on our Scientific Advisory Board.
  • The Scientific Advisory Board demonstrates our commitment to delivering innovative solutions and exceptional services to our clients, and we look forward to working closely with them to achieve our goals."
  • said Dr. Sofia Adolfsson, Scientific Officer and Head of Bioinformatics at TATAA.

TATAA Announces Formation of Scientific Advisory Board

Retrieved on: 
Tuesday, October 31, 2023
Drug development, OpenBiome, PPD, MIT, AstraZeneca, MPH, McMaster University, MD, Medicinal chemistry, Doctor of Philosophy, Research, ChromeOS, Internal medicine, Growth, Pharmacy, Novartis, Innate immune system, Medicine, Bristol Myers Squibb, Amgen, Drug discovery, Molecular biology, Biomarker, Nobel Prize, United States Air Force Scientific Advisory Board, SAB, Harvard University, Medical device, Pharmaceutical industry, Physiology, Fluid dynamics, Gastroenterology, Ultragenyx, TATAA, Western University, Bioanalysis

GOTHENBURG, Sweden, Oct. 31, 2023 /PRNewswire/ -- TATAA Biocenter (the "Company" or "TATAA"), a leading global CRO for high-quality molecular analysis, announced the formation of its Scientific Advisory Board ("SAB").

Key Points: 
  • GOTHENBURG, Sweden, Oct. 31, 2023 /PRNewswire/ -- TATAA Biocenter (the "Company" or "TATAA"), a leading global CRO for high-quality molecular analysis, announced the formation of its Scientific Advisory Board ("SAB").
  • "We are excited to have such a distinguished group of experts on our Scientific Advisory Board.
  • The Scientific Advisory Board demonstrates our commitment to delivering innovative solutions and exceptional services to our clients, and we look forward to working closely with them to achieve our goals."
  • said Dr. Sofia Adolfsson, Scientific Officer and Head of Bioinformatics at TATAA.

Breathing new life into patient care: Innovative partnership aims to transform interstitial lung disease support

Retrieved on: 
Wednesday, October 25, 2023
Patient, Research, COPD, McMaster Faculty of Engineering, Faculty, Engineering, McMaster University, Therapy, Periodic breathing, Firestone Institute for Respiratory Health, Transfusion-related acute lung injury, Life, Hope, McMaster, Student, Fibrosis, St. Joe, Health, Quality of life, St. Joseph's Healthcare Hamilton, Caregiver, Internet, Disease, Boehringer Ingelheim, Emotion, Confusion, Market access, Asthma, Partnership, ILD, Depression, Anxiety, Diagnosis, Empathy, Associate, Uncertainty, Mental health, Medical device, Nursing, BURLINGTON, Medicine

"Having the opportunity to work with ILD patients has been a deeply humbling and rewarding experience.

Key Points: 
  • "Having the opportunity to work with ILD patients has been a deeply humbling and rewarding experience.
  • "ILD is a complex, life-altering disease where Canadians often do not get the information they need at diagnosis.
  • Boehringer Ingelheim Canada, St. Joseph's Healthcare Hamilton, and McMaster University are committed to transforming the ILD patient experience.
  • Research is wide-ranging, from basic studies of animal models of lung disease (asthma, COPD, fibrosis) to clinical trials, epidemiological studies, and evaluative research.

Aktiia SA collaborates on landmark study led by McMaster University, the Private University of Liechtenstein, and the Dr. Risch Laboratory for the determination of cardiovascular risk factors on more than 2000 people

Retrieved on: 
Tuesday, October 24, 2023
Genetic, Health, McMaster University, Blood pressure, Publication, Research, Database, GAPP, Partnership, Professor, CMO, Private university, Pharmaceutical industry, Medical device

This collaboration aims to unlock the links between longitudinal blood pressure patterns and genetic, biomarker, imaging, and healthcare data, paving the way for groundbreaking discoveries in the field.

Key Points: 
  • This collaboration aims to unlock the links between longitudinal blood pressure patterns and genetic, biomarker, imaging, and healthcare data, paving the way for groundbreaking discoveries in the field.
  • As a pioneer in cuffless blood pressure monitoring, Aktiia is uniquely positioned to contribute valuable insights and data to the GAPP study, with little to no extra burden on the study participants.
  • "We are honored to collaborate with Professors Conen and Risch and the GAPP study investigators," said Jay Shah, CMO of Aktiia.
  • Aktiia and the GAPP study investigators eagerly anticipate the discoveries and insights that will emerge from the collaboration.

Aktiia SA collaborates on landmark study led by McMaster University, the Private University of Liechtenstein, and the Dr. Risch Laboratory for the determination of cardiovascular risk factors on more than 2000 people

Retrieved on: 
Tuesday, October 24, 2023
Genetic, Health, McMaster University, Blood pressure, Publication, Research, Database, GAPP, Partnership, Professor, CMO, Private university, Pharmaceutical industry, Medical device

This collaboration aims to unlock the links between longitudinal blood pressure patterns and genetic, biomarker, imaging, and healthcare data, paving the way for groundbreaking discoveries in the field.

Key Points: 
  • This collaboration aims to unlock the links between longitudinal blood pressure patterns and genetic, biomarker, imaging, and healthcare data, paving the way for groundbreaking discoveries in the field.
  • As a pioneer in cuffless blood pressure monitoring, Aktiia is uniquely positioned to contribute valuable insights and data to the GAPP study, with little to no extra burden on the study participants.
  • "We are honored to collaborate with Professors Conen and Risch and the GAPP study investigators," said Jay Shah, CMO of Aktiia.
  • Aktiia and the GAPP study investigators eagerly anticipate the discoveries and insights that will emerge from the collaboration.

Fortetropin Identified as Potential Solution for Muscle Loss Linked to Popular Weight Loss Products

Retrieved on: 
Thursday, October 19, 2023
Facial muscles, Myostatin, American College, Yolk, History of the University of California, Berkeley, Duke University, McMaster University, Weight loss, Atrophy, University of California, Berkeley, Research, Journal, Athlete, Metabolism, Leg, University, PLOS One, Immobilization, Woman, Weight, Appetite, Dietary supplement, CORP

CEDAR KNOLLS, N.J., Oct. 19, 2023 /PRNewswire-PRWeb/ --

Key Points: 
  • Preliminary observations by esteemed experts suggest that Fortetropin might be a promising solution to the muscle deterioration linked with certain mainstream weight loss products.
  • However, like many weight loss products, it can lead to muscle loss.
  • By combining a muscle health product like Fortetropin with a weight loss product, users should enjoy the weight loss benefits without the same degree of muscle depletion.
  • This suggests that Fortetropin supplementation can favor a conducive environment for muscle growth and as well as attenuate muscle loss.

A Game Changer: Exerkine Corporation Leap Frogs into its Commercial Phase

Retrieved on: 
Tuesday, October 17, 2023
Cardiovascular disease, Patent, Type 2 diabetes, FRCP, Partnership, News, The Wall Street Journal, Doctor of Philosophy, McMaster University, Obesity, CSO, Weight loss, Mitochondrion, Dementia, Safety, Hospital, Bell, Therapy, Facial muscles, ABC News, Clinical trial, CBC News, Exercise, Science, Skeletal muscle, DSM-IV codes, Business development, Research, Interleukin, Cognition, Pharmaceutical industry, Dietary supplement, The New York Times, MD

HAMILTON, Ontario, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Exerkine Corporation (the "Company" or "Exerkine") is pleased to announce that it has successfully transitioned from its pre-revenue development phase into commercial operations.

Key Points: 
  • HAMILTON, Ontario, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Exerkine Corporation (the "Company" or "Exerkine") is pleased to announce that it has successfully transitioned from its pre-revenue development phase into commercial operations.
  • Exerkine is poised to change this paradigm through proprietary products that are built and backed by science.
  • Utilizing advances in mitochondrial sciences, exercise physiology, and nutrition, Exerkine leverages pharmaceutical-industry R&D standards to create novel nutrition-based products.
  • As the founder, CEO and CSO of Exerkine, Dr. Tarnopolsky is applying his clinical and scientific expertise to lead Exerkine’s commercial and research development.

Ascendis Pharma Presents TransCon™ PTH (palopegteriparatide) Phase 3 52-Week Skeletal Dynamics Data at ASBMR 2023

Retrieved on: 
Monday, October 16, 2023
European, Hypoparathyroidism, McMaster University, CHMP, PTH, Bone, Patient, Pathway, Parathyroid hormone, Southern Transcon, Research, Clinical trial, American Society for Bone and Mineral Research, Poster, Pharmaceutical industry, Medicine

COPENHAGEN, Denmark, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) shared 52-week data from the open-label extension period of its ongoing Phase 3 PaTHway Trial of TransCon PTH (palopegteriparatide) showing that adults with chronic hypoparathyroidism, whose bones tend to be over-mineralized due to insufficient parathyroid hormone (PTH) exposure, trended toward a new skeletal steady state closer to age-appropriate norms with continued use of TransCon PTH. The results were consistent regardless of sex, menopausal status, or duration of disease and were consistent with results previously reported through Week 110 in the Company’s Phase 2 PaTH Forward Trial.

Key Points: 
  • The results were consistent regardless of sex, menopausal status, or duration of disease and were consistent with results previously reported through Week 110 in the Company’s Phase 2 PaTH Forward Trial.
  • On September 14, 2023, TransCon PTH received a positive CHMP opinion recommending approval in the European Union for the treatment of adults with chronic hypoparathyroidism.
  • TransCon PTH is also in development in the United States and Japan.
  • Registered attendees of ASMBR 2023 conference can access the abstract, poster, and presentation (#1114) through the conference organizer’s website .

Amolyt Pharma Announces Data on Prevalence of Bone Disease in Patients with Hypoparathyroidism and Favorable Bone Effects of Eneboparatide at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting

Retrieved on: 
Monday, October 16, 2023
Annual general meeting, Calcium, Hypoparathyroidism, McMaster University, Bone fracture, Bone disease, Society, American Society for Bone and Mineral Research, PTHR1, Homeostasis, Fracture, Phase 3, Osteoporosis, Medicine, DXA, Patient, PMF, Metabolic bone disease, Woman, Osteopenia, Quality of life, Medical imaging, Dietary supplement

LYON, France, and CAMBRDIGE, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced data from two posters that were presented at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting, which is being held October 13-16, 2023, in Vancouver, BC, Canada. The data include a prospective analysis of bone disease in patients with hypoparathyroidism from the Canadian National Hypoparathyroidism Registry with evidence of significant bone disease burden in postmenopausal females (PMF). In addition, data from both pre-clinical and clinical studies of eneboparatide continue to demonstrate its ability to restore balanced bone turnover, preserving bone integrity, while maintaining calcium homeostasis and normalizing urinary calcium.

Key Points: 
  • The data include a prospective analysis of bone disease in patients with hypoparathyroidism from the Canadian National Hypoparathyroidism Registry with evidence of significant bone disease burden in postmenopausal females (PMF).
  • In addition, data from both pre-clinical and clinical studies of eneboparatide continue to demonstrate its ability to restore balanced bone turnover, preserving bone integrity, while maintaining calcium homeostasis and normalizing urinary calcium.
  • “We’re very pleased to have a strong presence at this year’s ASBMR Annual Meeting.
  • These data increase our understanding of the relationship between hypoparathyroidism and bone strength.

Amolyt Pharma Announces Two Poster Presentations at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting

Retrieved on: 
Tuesday, October 3, 2023
American Society for Bone and Mineral Research, Metabolic bone disease, McMaster University, Society, Annual general meeting, Communications satellite

LYON, France, and CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced that it will present two posters at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting, which is being held October 13-16, 2023 in Vancouver, BC, Canada.

Key Points: 
  • LYON, France, and CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced that it will present two posters at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting, which is being held October 13-16, 2023 in Vancouver, BC, Canada.
  • Details of the presentations are as follows:
    Session Time: 1:30 – 3:00 p.m. PT (4:30 – 6:00 p.m.
  • ET)
    Author/Presenter: Salma Hussein, M.D.
  • (Clinical Fellow of Metabolic Bone Disease, McMaster University)
    Title: Eneboparatide, A Novel Investigational PTH1R Agonist, Maintains Calcium Homeostasis Without Deleterious Effects on Bone
    Session Time: 1:30 – 3:00 p.m. PT (4:30 – 6:00 p.m.